Clinical Trial News - BioPharma Dive
4 days ago · Safety concerns Keros observed in a Phase 2 trial triggered a stock selloff for what had been one of the sector’s most successful initial public offerings of the last four years, according to BioPharma Dive data. While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that ...
10 clinical trials to watch in the first half of 2024
Jan 2, 2024 · Pain drug studies are also notoriously difficult, as the trial goals are subjective measures that can be confounded by a placebo response. “Basically, pain is really hard,” Stifel analysts wrote. In early 2024, Vertex will release results from a pair of placebo-controlled studies and a third, single-arm trial, in different forms of acute ...
10 clinical trials to watch in the second half of 2024
Jul 1, 2024 · Results from a Phase 3 trial of a drug called dapirolizumab pegol are expected shortly and, if positive, could give Biogen a much-needed win. Biogen developed the drug, which targets an immune cell protein called CD40L, with UCB and would jointly sell it if it were to reach the market. The trial focuses on the most common and serious type of lupus.
Clinical Trial News | BioPharma Dive
Nov 11, 2024 · With the new clinical trial diversity guidelines, the combination of EHR data and AI will be essential. Oct. 28, 2024 Adobe Stock/# 501471652, by Puwasit Inyavileart
10 clinical trials to watch in the first half of 2022
Jan 3, 2022 · Faced with conflicting clinical trial data, the FDA chose to clear Aduhelm based on how it is thought to work, elevating a long-debated and unproven disease hypothesis in the process. Over the course of 2022, study results from Roche and Eisai could offer supporting evidence for Aduhelm, its developer Biogen and the FDA, or throw the drug's ...
Clinical Trial News | BioPharma Dive
Mar 26, 2024 · Improving clinical trial design with real-world data Leveraging real-world data (RWD) transforms global clinical trials, enhancing patient engagement and improving regulatory decision-making. March 25, 2024
Clinical Trial News | BioPharma Dive
Jun 3, 2024 · Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting give a peek at anticipated datasets from Immunocore, Merus, J&J and Merck & Co. By BioPharma Dive staff • Updated May 24, 2024
Clinical Trial News | BioPharma Dive
Aug 1, 2024 · Bridging science and humanity: Systems thinking in clinical trial design Benefits of adopting the systems thinking approach in clinical trial design. By Clare Campbell-Cooper, Global Head of Digital Health and Innovation at FORTREA • June 24, 2024
Clinical Trial News | BioPharma Dive
Sep 14, 2024 · The trial setbacks for Merck’s best-selling drug, which faces patent expiration in 2028, are a blow to the company’s plans for further indication expansion. By Jonathan Gardner • Aug. 29, 2024
10 clinical trials to watch in the second half of 2023
Jun 28, 2023 · Promising results from this trial, both earlier and again at ASCO, have heightened anticipation for a larger Phase 3 trial J&J is running that pits the combination against Tagrisso. The outcome, expected later this year, could either cement Tagrisso’s incumbent status, or crown a new challenger to AstraZeneca’s drug.